Congress in Spain were a major feature of research news last week, including those from Pfizer on it ponsegromab in cancer ...

Basel, Switzerland Friday, September 20, 2024, 13:00 Hrs [IST] ...

Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...

The Roivant company is dedicated to developing and commercializing innovative therapeutics in immune-dermatology.

As part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis ...

Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Organon (OGN – Research Report), retaining the price target of ...

Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama, ...

Organon & Co (NYSE:OGN) has agreed to acquire Roivant Sciences Ltd’s (NASDAQ:ROIV) Dermavant Sciences Ltd, which is focused ...

Roivant Sciences Ltd. has sold another company, this time offering up Dermavant Sciences Ltd. to Organon & Co. for $1.2 ...

18, 2024 (GLOBE NEWSWIRE) -- Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives, and Dermavant Sciences Ltd. announced today that ...

Women’s health specialist Organon has entered into a definitive agreement to acquire Dermavant Sciences, a Roivant company.

Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, ...